B. Metzler seel. Sohn & Co. AG Sells 5,429 Shares of Insmed, Inc. $INSM

B. Metzler seel. Sohn & Co. AG reduced its position in shares of Insmed, Inc. (NASDAQ:INSM) by 51.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,081 shares of the biopharmaceutical company’s stock after selling 5,429 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Insmed were worth $732,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Natixis Advisors LLC raised its position in shares of Insmed by 11.3% in the third quarter. Natixis Advisors LLC now owns 39,450 shares of the biopharmaceutical company’s stock worth $5,681,000 after buying an additional 3,991 shares in the last quarter. First Trust Advisors LP grew its position in Insmed by 407.8% during the third quarter. First Trust Advisors LP now owns 240,646 shares of the biopharmaceutical company’s stock worth $34,655,000 after buying an additional 193,254 shares in the last quarter. Neuberger Berman Group LLC increased its stake in Insmed by 1,277.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 150,106 shares of the biopharmaceutical company’s stock worth $21,617,000 after acquiring an additional 139,211 shares during the last quarter. Gabelli Funds LLC bought a new position in Insmed in the 3rd quarter worth about $207,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in shares of Insmed in the 3rd quarter valued at about $316,000.

Wall Street Analyst Weigh In

INSM has been the subject of a number of research analyst reports. Barclays began coverage on Insmed in a report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. TD Cowen set a $241.00 target price on shares of Insmed in a research report on Thursday, December 18th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research note on Friday, January 23rd. Finally, Bank of America set a $203.00 price target on shares of Insmed in a report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Insmed has a consensus rating of “Buy” and a consensus price target of $207.52.

Insmed Price Performance

Shares of Insmed stock opened at $139.40 on Thursday. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The stock has a market capitalization of $30.05 billion, a price-to-earnings ratio of -21.75 and a beta of 1.13. The company has a fifty day moving average of $156.62 and a 200-day moving average of $165.81. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.32) EPS. Equities research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the completion of the sale, the insider owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. This represents a 5.89% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 189,651 shares of company stock worth $31,784,545. Company insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.